DelveInsight launched a new report on Pulmonary Arterial Hypertension Epidemiology Forecast, 2030.
Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hypertension that is characterized by elevated pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) in blood vessels carrying the blood from the right side of the heart through lungs. It occurs due to the tightening and stiffening of the small pulmonary arteries leading to the right ventricular dysfunction and vessel obstruction.
DelveInsight’s ‘Pulmonary Arterial Hypertension Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Pulmonary Arterial Hypertension epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Some of the key highlights from the Pulmonary Arterial Hypertension Epidemiology Report:
As per the study “Prevalence of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension in the United States” conducted by Kirson et.al. (2011), the prevalence of Pulmonary Arterial Hypertension was observed to be 109 per million individuals (PMI) among the population of fewer than 65 years old. Prevalence of Pulmonary Arterial Hypertension was found to be 451 per million individuals (PMI) among age groups older than 65 years.
Emerging therapies such as Aurora-GT, Ralinepag, Sotatercept, Bardoxolone methyl, are expected to have a significant impact on the Pulmonary Arterial Hypertension market in the coming years.
Among the EU-5 countries, the XXXX accounts for the highest market size for Pulmonary Arterial Hypertension (PAH) in 2018.
Visit for more @ Pulmonary Arterial Hypertension Epidemiology Insights
Scope of the Pulmonary Arterial Hypertension Epidemiology report:
The Pulmonary Arterial Hypertension report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
The Pulmonary Arterial Hypertension Epidemiology Report and Model provide an overview of the risk factors and global trends of Pulmonary Arterial Hypertension in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
The report provides insight into the historical and forecasted patient pool of Pulmonary Arterial Hypertension in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
The report helps to recognize the growth opportunities in the 7MM concerning the patient population
The report assesses the disease risk and burden and highlights the unmet needs of Pulmonary Arterial Hypertension
The report provides the segmentation of the Pulmonary Arterial Hypertension epidemiology
Table of Contents:
1. Key Insights
2. Executive Summary of Pulmonary Arterial Hypertension
3.Pulmonary Arterial Hypertension Epidemiology Overview at a Glance
4.Pulmonary Arterial Hypertension: Disease Background and Overview
5. Epidemiology and Patient Population
6. Case Reports
7. Country Wise-Epidemiology of Pulmonary Arterial Hypertension
9. DelveInsight Capabilities
DelveInsight’s ‘Pulmonary Arterial Hypertension-Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the MM, historical and forecasted epidemiology as well as the MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
“Pulmonary Arterial Hypertension Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Pulmonary Arterial Hypertension market. A detailed picture of the Pulmonary Arterial Hypertension pipeline landscape is provided, which includes the disease overview and Pulmonary Arterial Hypertension treatment guidelines.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States